Calming the (Cytokine) Storm: Dimethyl Fumarate as a Therapeutic Candidate for COVID-19
Cara A. Timpani, Emma Rybalka
Abstract
COVID-19 has rapidly spread worldwide and incidences of hospitalisation from respiratory distress are significant. While a vaccine is in the pipeline, there is urgency for therapeutic options to address the immune dysregulation, hyperinflammation and oxidative stress that can lead to death. Given the shared pathogenesis of severe cases of COVID-19 with aspects of multiple sclerosis and psoriasis, we propose dimethyl fumarate as a viable treatment option. Currently approved for multiple sclerosis and psoriasis, dimethyl fumarate is an immunomodulatory, anti-inflammatory and anti-oxidative drug that could be rapidly implemented into the clinic to calm the cytokine storm which drives severe COVID-19.
Topics & Concepts
Cytokine stormDimethyl fumaratePsoriasisMedicineMultiple sclerosisCoronavirus disease 2019 (COVID-19)Immune systemCytokineImmunologyPharmacologyInternal medicineDiseaseInfectious disease (medical specialty)Long-Term Effects of COVID-19SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies